HCV protease inhibitor and non-nucleoside polymerase inhibitor combination

This page covers all HCV protease inhibitor and non-nucleoside polymerase inhibitor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HCV NS3/4A serine protease and NS5B RNA-dependent RNA polymerase.

Targets

HCV NS3/4A serine protease and NS5B RNA-dependent RNA polymerase

Phase 3 pipeline (1)

• ABT-450/r/ABT-267, ABT-333 · AbbVie (prior sponsor, Abbott) · Virology / Hepatology
  This combination of hepatitis C virus (HCV) protease inhibitors and a non-nucleoside polymerase inhibitor blocks viral replication by inhibiting essential HCV enzymes.

Patent intelligence

• hcv protease inhibitor and non nucleoside polymerase inhibitor combination patent landscape — aggregated cliff calendar, attackable patents, originator estates